REGENXBIO Inc.

NasdaqGS:RGNX 주식 보고서

시가총액: US$477.1m

REGENXBIO 관리

관리 기준 확인 2/4

REGENXBIO CEO는 Curran Simpson, Jul2024 에 임명되었습니다 의 임기는 1년 미만입니다. 총 연간 보상은 $ 2.95M, 17.4% 로 구성됩니다. 17.4% 급여 및 82.6% 보너스(회사 주식 및 옵션 포함). 는 $ 147.91K 가치에 해당하는 회사 주식의 0.031% 직접 소유합니다. 147.91K. 경영진과 이사회의 평균 재임 기간은 각각 5.9 년과 7.4 년입니다.

주요 정보

Curran Simpson

최고 경영자

US$3.0m

총 보상

CEO 급여 비율17.4%
CEO 임기less than a year
CEO 소유권0.03%
경영진 평균 재임 기간5.9yrs
이사회 평균 재임 기간7.4yrs

최근 관리 업데이트

Recent updates

REGENXBIO: With Additional MPS II Data, Program Advancement Remains On Track

Oct 31

Does REGENXBIO (NASDAQ:RGNX) Have A Healthy Balance Sheet?

Sep 12
Does REGENXBIO (NASDAQ:RGNX) Have A Healthy Balance Sheet?

Regenxbio: RGX-121 Could Achieve A First For Rare Neurodegenerative Disorder

Aug 06

REGENXBIO Inc. (NASDAQ:RGNX) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 04
REGENXBIO Inc. (NASDAQ:RGNX) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price

Jul 26
Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price

Regenxbio: Transforming Gene Therapy With Innovative AAV Treatments, Strong Buy

Jun 11

REGENXBIO Inc. (NASDAQ:RGNX) Analysts Are Cutting Their Estimates: Here's What You Need To Know

May 11
REGENXBIO Inc. (NASDAQ:RGNX) Analysts Are Cutting Their Estimates: Here's What You Need To Know

REGENXBIO Inc. (NASDAQ:RGNX) Not Doing Enough For Some Investors As Its Shares Slump 26%

Apr 25
REGENXBIO Inc. (NASDAQ:RGNX) Not Doing Enough For Some Investors As Its Shares Slump 26%

Regenxbio: DMD Program Lends Additional Credibility To NAV Technology Platform

Mar 11

Analysts Just Slashed Their REGENXBIO Inc. (NASDAQ:RGNX) EPS Numbers

Mar 07
Analysts Just Slashed Their REGENXBIO Inc. (NASDAQ:RGNX) EPS Numbers

Improved Revenues Required Before REGENXBIO Inc. (NASDAQ:RGNX) Stock's 75% Jump Looks Justified

Mar 05
Improved Revenues Required Before REGENXBIO Inc. (NASDAQ:RGNX) Stock's 75% Jump Looks Justified

Earnings Update: REGENXBIO Inc. (NASDAQ:RGNX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Mar 02
Earnings Update: REGENXBIO Inc. (NASDAQ:RGNX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Regenxbio: Robust Data, Decent Cash, Never Ending Trials, Buying At Dips

Jan 19

There's No Escaping REGENXBIO Inc.'s (NASDAQ:RGNX) Muted Revenues

Dec 21
There's No Escaping REGENXBIO Inc.'s (NASDAQ:RGNX) Muted Revenues

We Think REGENXBIO (NASDAQ:RGNX) Needs To Drive Business Growth Carefully

Nov 09
We Think REGENXBIO (NASDAQ:RGNX) Needs To Drive Business Growth Carefully

Will REGENXBIO (NASDAQ:RGNX) Spend Its Cash Wisely?

Aug 08
Will REGENXBIO (NASDAQ:RGNX) Spend Its Cash Wisely?

REGENXBIO Inc. (NASDAQ:RGNX) Analysts Just Trimmed Their Revenue Forecasts By 12%

May 11
REGENXBIO Inc. (NASDAQ:RGNX) Analysts Just Trimmed Their Revenue Forecasts By 12%

Here's Why We're Watching REGENXBIO's (NASDAQ:RGNX) Cash Burn Situation

May 08
Here's Why We're Watching REGENXBIO's (NASDAQ:RGNX) Cash Burn Situation

Analysts Are More Bearish On REGENXBIO Inc. (NASDAQ:RGNX) Than They Used To Be

Mar 05
Analysts Are More Bearish On REGENXBIO Inc. (NASDAQ:RGNX) Than They Used To Be

CEO 보상 분석

Curran Simpson 의 보수는 REGENXBIO 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2024n/an/a

-US$239m

Jun 30 2024n/an/a

-US$241m

Mar 31 2024n/an/a

-US$260m

Dec 31 2023US$3mUS$513k

-US$263m

Sep 30 2023n/an/a

-US$261m

Jun 30 2023n/an/a

-US$274m

Mar 31 2023n/an/a

-US$270m

Dec 31 2022US$2mUS$475k

-US$280m

Sep 30 2022n/an/a

US$74m

Jun 30 2022n/an/a

US$91m

Mar 31 2022n/an/a

US$101m

Dec 31 2021US$3mUS$448k

US$128m

Sep 30 2021n/an/a

-US$212m

Jun 30 2021n/an/a

-US$145m

Mar 31 2021n/an/a

-US$121m

Dec 31 2020US$2mUS$428k

-US$111m

Sep 30 2020n/an/a

-US$91m

Jun 30 2020n/an/a

-US$135m

Mar 31 2020n/an/a

-US$103m

Dec 31 2019US$2mUS$382k

-US$95m

Sep 30 2019n/an/a

-US$64m

Jun 30 2019n/an/a

-US$49m

Mar 31 2019n/an/a

-US$37m

Dec 31 2018US$2mUS$371k

US$100m

Sep 30 2018n/an/a

US$80m

Jun 30 2018n/an/a

US$78m

Mar 31 2018n/an/a

US$53m

Dec 31 2017US$912kUS$361k

-US$73m

보상 대 시장: Curran 의 총 보상 ($USD 2.95M )은 US 시장( $USD 2.24M ).

보상과 수익: 회사가 수익성이 없는 동안 Curran 의 보상이 증가했습니다.

CEO

Curran Simpson (62 yo)

less than a year

테뉴어

US$2,950,002

보상

Mr. Curran M. Simpson, M.S., had been the Chief Operating Officer at REGENXBIO Inc. since January 2023 until July 01, 2024 and served as its Executive Vice President until July 01, 2024 and serves as its P...

리더십 팀

이름위치테뉴어보상소유권
Curran Simpson
Presidentless than a yearUS$2.95m0.031%
$ 147.9k
Olivier Danos
Executive VP & Chief Scientific Officer7.7yrsUS$2.99m0.061%
$ 289.4k
Vittal Vasista
Advisorless than a yearUS$2.62m0.38%
$ 1.8m
Stephen Pakola
Executive VP & Chief Medical Officer5.6yrsUS$3.31m0%
$ 0
Mitchell Chan
Executive VP & CFOless than a year데이터 없음데이터 없음
Patrick Christmas
Executive VP & Chief Legal Officer8.3yrsUS$3.44m0.046%
$ 219.5k
Shiva Fritsch
Chief Communications & People Officer7.1yrs데이터 없음데이터 없음
Ram Palanki
Executive VP of Commercial Strategy & Operations6.3yrs데이터 없음데이터 없음

5.9yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 관리: RGNX 의 관리팀은 노련하고 경험 (평균 재직 기간 5.9 년)입니다.

이사회 구성원

이름위치테뉴어보상소유권
Curran Simpson
Presidentless than a yearUS$2.95m0.031%
$ 147.9k
David Stump
Independent Director9.1yrsUS$339.98k0.0061%
$ 29.0k
George Migausky
Independent Director3.2yrsUS$339.98k0.0061%
$ 29.0k
Argeris Karabelas
Independent Director9.5yrsUS$352.48k0.013%
$ 62.6k
Inder Verma
Member of Scientific Advisorno data데이터 없음데이터 없음
Allan Fox
Director15.8yrsUS$354.98k6.39%
$ 30.5m
Judith Swain
Member of Scientific Advisorno data데이터 없음데이터 없음
Alexandra Glucksmann
Independent Director6.5yrsUS$327.48k0.0061%
$ 29.0k
Daniel Tassé
Lead Independent Director8.3yrsUS$334.98k0.0061%
$ 29.0k
Jean Bennett
Independent Director3.2yrsUS$324.98k0.0061%
$ 29.0k
Kenneth Mills
Chairman15.7yrsUS$5.92m0.63%
$ 3.0m
Jennifer Zachary
Independent Director2.4yrsUS$329.98k0.0040%
$ 19.3k

7.4yrs

평균 재임 기간

69.5yo

평균 연령

경험이 풍부한 이사회: RGNX 의 이사회는 경험(평균 재직 기간 7.4 년)으로 간주됩니다.